Small Split Doses of CD34(+) Peripheral Blood Stem Cells to Support Repeated Cycles of Nonmyeloablative Chemotherapy

Cumulative myelosuppression is the main limiting factor for administration of repeated cycles of chemotherapy. We present a case series of five pediatric patients with high-risk solid malignancies who received small split peripheral blood stem cells (PBSC) doses of less than 1 × 10(6)/kg CD34(+) cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Yankelevich, Maxim, Savasan, Sureyya, Dolgopolov, Igor, Chu, Roland, Mentkevich, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702414/
https://www.ncbi.nlm.nih.gov/pubmed/29259833
http://dx.doi.org/10.1155/2017/4184879
Descripción
Sumario:Cumulative myelosuppression is the main limiting factor for administration of repeated cycles of chemotherapy. We present a case series of five pediatric patients with high-risk solid malignancies who received small split peripheral blood stem cells (PBSC) doses of less than 1 × 10(6)/kg CD34(+) cells obtained after a single leukapheresis procedure and given after repeated cycles of ICE (ifosfamide, carboplatin, and etoposide) chemotherapy. Mean duration to absolute neutrophil count (ANC) recovery to >1000/mm(3) and platelet recovery to >50 × 10(3)/mm(3) was 17.1 and 24.3 days. Using split doses of PBSC prevented prolonged neutropenia after repeated cycles of submyeloablative chemotherapy.

Ejemplares similares